Slingshot members are tracking this event:
Global Blood Therapeutics Announces Publication of Preclinical GBT440 Results in British Journal of Haematology that Support Sickle Cell Disease (SCD) Program
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
"Our preclinical work has developed a foundation of evidence that GBT440 is a potent inhibitor of the polymerization of HbS. We continue to build on these data with our ongoing Phase 1/2 study, which has shown that GBT440 was well tolerated over 90 days of dosing, and that all SCD patients who received multiple doses of GBT440 exhibited improvements in one or more clinical markers of hemolysis and anemia," said Ted W. Love, M.D., chief executive officer of GBT. "Our next step is to initiate a pivotal trial in adults with SCD later this year."
A major driver of the pathophysiology of sickle cell disease (SCD) is polymerization of deoxygenated haemoglobin S (HbS), which leads to sickling and destruction of red blood cells (RBCs) and end-organ damage. Pharmacologically increasing the proportion of oxygenated HbS in RBCs may inhibit polymerization, prevent sickling and provide long term disease modification. We report that GBT440, a small molecule which binds to the N-terminal α chain of Hb, increases HbS affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of RBCs. Moreover, in a murine model of SCD, GBT440 extends the half-life of RBCs, reduces reticulocyte counts and prevents ex vivo RBC sickling. Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute. Thus, GBT440 has the potential for clinical use as a disease-modifying agent in sickle cell patients.
Slingshot Insights Explained
Jul 08, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Gbt440, British Journnal Of Hematology, Sickle Cell Disease